P24. Epidemiologic, clinical characteristics of elderly non-small lung cancer patients treated in a single institution
CELCC 2014 Abstracts

P24. Epidemiologic, clinical characteristics of elderly non-small lung cancer patients treated in a single institution

Michail Vaslamatzis1, Nektarios Alevizopoulos1, Theodoros Tegos1, Charalambos Zoublios1, Theodora Kapou1, Lambrini Kyriou2, Charalambos Stathopoulos1, Georgios Gkoumas1, Elisavet Patila1, Aikaterini Delaki1

1Evaggelismos General Hospital Oncology Department, Athens, Greece; 2Evaggelismos General Hospital Biochemistry Department, Athens, Greece


Background: Up to 40% newly diagnosed non-small cell lung cancer (NSCLC) patients are ≥70 years, with comorbidities which affect standard treatment deliver necessity Chemotherapy planning remains a challenge, based on risk-benefit ratio.

Aim: To record the epidemiological, clinical, laboratory data & outcome in the 160 pts [95 (59%) men, 65 (41%) women], with NSCLC ≥70 years, median age 75 [70-86] y, stage IIIB+IV, consecutively admitted in our Unit, between January 2007 to June 2014.

Methods and results: All documented 84 pts (52.5%, 70-75 y, group A), “young-elderly” & 76 (47.5%, 76-86 y, group B), “elderly-elderly”. Median ECOG 2 (0-3). Active or ex-smokers were 152 (95%), passive 8 (5%). Presentation symptoms: haemoptysis 59 (37%) total, 38 (45%) & 21 (28%) respectively, cough 46 (29%), 29 (35%) & 17 (22%) dyspnoea in 16 (10%), 7 (8%) & 9 (12%), chest discomfort in 9 (6%) L, 4 (5%) & 5 (7%), cervical lymphadenopathy in 13 (8%), 3 (4%) & 10 (13%), SVC in 12 (7.5%), 3 (4%) & 9 (12%), Pancoast 5 (3%) IIIB NSCLC, 3 (4%) & 2 (3%) respectively. Paraneoplastic: neuromyopathy, hypercalcemia, phlebitis, diabetes, SIADH in 1, 2, 1, 1 & 8 (5%) respectively. Adenoca 69(43%), SCC 49 (31%), large cell 8 (5%), adenoSC 16 (10%) & neuroendocrine 18 (11%). SCC & adenoSCC had 29 (35%) & 35 (46%), in A/B. Osteoarthropathy found in 61 (38%) pts, 33 (48%) adenoca vs. 28 (31%) with non. Stage IV 142 pts, metastatic in liver, bones, adrenal, lung, brain, 106 (75%), 88 (62%), 56 (39%), 42 (30%), 28 (20%).

Comorbidities: Hypertension: 138 (86%), A/B: 68/73; COBD: 130 (81%), A/B: 66/64; DIABETES: 122 (76%), A/B: 56/66; Ischemic heart failure in 114 (71%), A/B: 54/60; Dyslipidemia: 86 (54%), A/B: 39/47; Low bone density: 71 (41%), A/B: 31/40; Hypothyroidism: 36 (22.5%), A/B: 20/16; Parkinson: 17 (11%), A/B: 9/8 ; ≥3 comorbidities had 36/84 (43%) & 41/76 (54%) pts of A/B; Elevated LDH in 131(81%), A/B: 67/64. Median creatinine: 1.5 mg/dL; A/B: 1.5 (1.1-1.9)/1.5 (0.9-2) mg/dL.

Conclusions: Elderly NSCLC pts: 1. Prior therapeutic decision evaluation of PS/comorbidities is hallmark; 2. Evaluation of medical comorbidities is crucial prior any therapeutic design.

Keywords: Non-small cell lung cancer (NSCLC); elderly


doi: 10.3978/j.issn.2218-6751.2014.AB036


Cite this article as: Vaslamatzis M, Alevizopoulos N, Tegos T, Zoublios C, Kapou T, Kyriou L, Stathopoulos C, Gkoumas G, Patila E, Delaki A. Epidemiologic, clinical characteristics of elderly non-small lung cancer patients treated in a single institution. Transl Lung Cancer Res 2014;3(5):AB036. doi: 10.3978/j.issn.2218-6751.2014.AB036

Article Options

Download Citation